Sign in with Google. Opens in new tab
ENTITY
SMARTSCORE: 3/5
Astellas Pharma

Astellas Pharma (4503 JP)

156
Analysis
Health CareJapan
Astellas Pharma Inc. is a pharmaceutical company committed to the therapeutic fields of Urology, Immunology including Transplantation and Infectious Diseases, Oncology, Neuroscience and DM Complications and Metabolic Diseases. With over 17,000 global employees, Astellas researches, develops, manufactures, and promotes its prescription drugs through subsidiaries in the US, Europe, and Asia
more
bullishOtsuka Holdings
08 Nov 2024 13:51

Otsuka Holdings (4578 JP): Revenue and Profit Continue to Rise, Rexulti Remains Key

​During 9M24, Otsuka reported 19% growth in revenue from pharmaceuticals segment to ¥1201B, mainly driven by a 28% growth in Rexulti to ¥196B. FDA...

Logo
610 Views
Share
bullishSumitomo Pharma
05 Nov 2024 15:47

Sumitomo Pharma (4506 JP): Challenges Remain, But Slowly Getting There; North America Remains Key

​Sumitomo Pharma sees revenue growth in H1FY25, while losses are narrowing due to restructuring. The company is expected to report profit in H2FY25...

Logo
305 Views
Share
02 Nov 2024 23:30

APAC Healthcare Weekly (Nov 3)- Eisai, Takeda, Shionogi, Astellas Pharma, Celltrion, Wuxi AppTec

Large APAC healthcare companies are reporting mixed earnings. Demography will play a key role in ensuring how the overall domestic demand scenario...

Logo
691 Views
Share
29 Oct 2024 14:56

Chugai Pharmaceutical (4519 JP): Export Drives Growth; New Products To Relieve Domestic Market Pain

​Chugai reported 45% growth in overseas sales in 3Q24, driven by Hemlibra. The company raised 2024 guidance, which calls for revenue and core...

Logo
342 Views
Share
26 Oct 2024 23:30

APAC Healthcare Weekly (Oct 27)- Samsung Biologics, Celltrion, Astellas, Otsuka, Legend, and Zai Lab

Samsung Biologics secures largest ever contract, Celltrion announced KRW100B buyback, Astellas Pharma got label expansion approval for Vyloy,...

Logo
586 Views
Share
x